Q-omics provides the consensus-scored IGLV10-67 profile across patient tissues and cancer cell-line models. IGLV10-67 expression is associated with patient survival in 8 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, IGLV10-67 is differentially expressed in 4, with the highest sampling consensus in COAD. Additionally, IGLV10-67 RNA expression shows 4,631 significant gene co-expression associations, with the highest sampling consensus in UCEC. Together, these results highlight KICH, COAD, and UCEC as cancer lineages where IGLV10-67 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IGLV10-67 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IGLV10-67 survival associations across molecular data types. IGLV10-67 RNA expression shows survival associations in the most cancer types (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IGLV10-67 RNA expression–survival associations across cancer types. High IGLV10-67 expression shows unfavorable associations in KICH, ESCA, LGG, THYM and THCA, but favorable associations in LUAD. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for IGLV10-67 RNA expression.
This table summarizes IGLV10-67 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for IGLV10-67. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IGLV10-67 shows lower tumor expression in COAD, READ and LUSC and higher tumor expression in LUAD. The COAD box plot shows higher IGLV10-67 RNA expression in normal versus tumor tissue (log2 FC = −0.233, t-test p < 0.001).
This table shows molecular features associated with IGLV10-67 in patient tissues and cancer cell lines. In patient samples, IGLV10-67 shows the broadest associations at the RNA and protein expression levels, with UCEC recurring as the lineage with the largest associated feature set.
